Meshima Anti-Angiogenesis: Cutting Off Tumor Blood Supply

Meshima (Phellinus linteus)

3 anti-angiogenic pathways

Laboratory and animal studies have identified three distinct mechanisms by which Phellinus linteus inhibits tumor blood vessel formation, operating at different points in the angiogenesis cascade.

Sliva D, Experimental and Therapeutic Medicine, 2010

AKT→VEGF

upstream signaling suppressed in breast cancer cells (Sliva 2008)

VEGFR-2

receptor phosphorylation directly blocked in endothelial cells (Lee 2010)

Wnt/β-catenin

third pathway disrupted in colon cancer xenografts (Song 2011)

Sliva D, Experimental and Therapeutic Medicine, 2010

View as image ↗

A tumor can't grow beyond about 2 millimeters without recruiting a new blood supply. Below that size, oxygen and nutrients diffuse in from surrounding tissue. Above it, the tumor suffocates unless it can signal blood vessels to grow toward it. The molecule it uses to send that signal is VEGF (vascular endothelial growth factor), and blocking VEGF has become one of the central strategies in cancer pharmacology, producing approved drugs like bevacizumab.

Laboratory and animal studies of meshima (Phellinus linteus) show the mushroom disrupts tumor angiogenesis at not one but three distinct points in this process. It reduces how much VEGF cancer cells produce, blocks the receptor that VEGF activates on blood vessel cells, and in colon cancer models, disrupts a third signaling pathway that governs blood vessel formation through an entirely different molecular route.

This article covers the three mechanisms and the studies behind each of them. For a foundational introduction to meshima and its biology, see What Is Meshima Mushroom. For a detailed breakdown of the compounds responsible for these effects, see Phellinus linteus Bioactive Compounds.

Why Anti-Angiogenesis Matters and Where Meshima Fits In

The 2-millimeter limit comes from the physics of oxygen diffusion. Cells at the surface of a small cluster receive enough oxygen from nearby capillaries. Cells deeper in the cluster don't. At roughly 2mm across, a tumor reaches the point where diffusion can no longer feed all its cells. From there, it either stops growing or recruits its own blood supply.

It recruits that supply by secreting VEGF. This protein is a specific signal to the endothelial cells that line blood vessel walls: grow toward me, form new capillaries, extend my vascular network. VEGF binds to a receptor on endothelial cells called VEGFR-2, which triggers the signaling cascade that causes those cells to proliferate, migrate, and organize into tube-shaped capillaries.

The pharmaceutical approach to blocking this process involves either neutralizing VEGF directly (bevacizumab, an antibody that binds free VEGF before it reaches cells) or blocking VEGFR-2 from being activated (sorafenib and sunitinib, which prevent the receptor from passing its signal into the cell). These drugs are used in several cancer types and have documented clinical efficacy.

Phellinus linteus appears to interfere with this process through two of those same approach points, plus a third one that the pharmaceutical drugs don't target. A 2010 review by Sliva catalogued PL's anti-tumor properties across multiple cancer models: anti-proliferative, pro-apoptotic, anti-invasive, and specifically anti-angiogenic, identifying AKT inhibition and VEGF suppression as central mechanisms.^[3]

Pathway 1: Suppressing VEGF at the Source

The first mechanism works upstream of VEGF itself. Inside cancer cells, a signaling protein called AKT acts as a driver of VEGF production. When AKT is active (phosphorylated), it promotes the transcription of VEGF, meaning the cancer cell produces and secretes VEGF into the surrounding tissue. Blocking AKT reduces VEGF secretion at the source, before the protein even reaches blood vessel cells.

Sliva et al. (2008) tested Phellinus linteus extract on MDA-MB-231 cells, a highly aggressive triple-negative breast cancer line, and measured the results at multiple levels.^[2] VEGF secretion from the treated cells decreased in a dose-dependent pattern: more PL extract meant less VEGF released into the culture medium. The study also measured AKT phosphorylation directly: phosphorylation at Thr308 and Ser473, the two sites that switch AKT into its active state, were both suppressed by the treatment. Separately, the extract inhibited capillary morphogenesis in human aortic endothelial cells.

The significance of the AKT findings is that they explain the VEGF suppression mechanistically. It's not that PL is directly inactivating VEGF or binding it like an antibody. It's that the cancer cell's own VEGF production machinery is being turned down. The cancer cell is producing less of the signal that would recruit blood vessels toward it.

For a deeper analysis of the VEGF suppression data and what the dose-response numbers mean, see Meshima and VEGF Suppression.

Pathway 2: Blocking VEGF at the Receiver

The second mechanism works downstream: even if a cancer cell secretes VEGF, the signal can be blocked at the receiver end, on the endothelial cells that would otherwise respond by growing new capillaries.

VEGF triggers its effects by binding to VEGFR-2 on the surface of endothelial cells. This binding causes VEGFR-2 to phosphorylate (activate itself), which triggers the signaling cascade inside the cell: proliferation, migration, and tube formation. Blocking this phosphorylation step prevents the cascade from starting, even if VEGF is present in the tissue.

Lee et al. (2010) tested the methanol extract of Phellinus linteus and its fractions on human umbilical vein endothelial cells (HUVECs), the standard laboratory model for studying vascular responses.^[1] HUVECs are used because they behave similarly to the endothelial cells in tumor vasculature. The PL extract inhibited three distinct endothelial cell behaviors that are required for new vessel formation: proliferation (cells dividing), migration (cells moving toward the tumor), and tube formation (cells organizing into hollow, capillary-like structures). VEGFR-2 phosphorylation was directly suppressed.

Lee et al. also tested angiogenesis in a whole-organism model: the chick chorioallantoic membrane (CAM) assay. The CAM is the membrane inside a fertilized chick egg that contains a dense, growing vascular network, and it's widely used to test whether compounds inhibit real blood vessel formation in living tissue. PL extract reduced new vessel formation in the CAM model, confirming that the effects seen in cell culture translate to an in vivo system.

Two points in the VEGF pathway blocked independently: the tumor cell's signal goes out, but the receiver can't hear it.

Pathway 3: The Colon Cancer Angle and Wnt Signaling

The first two pathways were identified primarily in breast cancer models. Song et al. (2011) extended the anti-angiogenic evidence into colorectal cancer and identified a third molecular route: Wnt/beta-catenin signaling.^[4]

Wnt signaling is a pathway that governs cell fate, proliferation, and in the context of blood vessels, is involved in governing angiogenesis during both development and disease. In colorectal cancer specifically, Wnt/beta-catenin signaling is often aberrantly activated (SW480 cells, used in the Song 2011 study, carry a common Wnt-activating mutation). When the Wnt pathway is overactive in cancer cells, it promotes both tumor growth and the formation of new blood vessels to feed that growth.

Song et al. used a protein-bound polysaccharide extract from Phellinus linteus in SW480 colon tumor xenografts in mice. The treated tumors showed reduced microvessel density (fewer blood vessels per area of tumor tissue), reduced invasiveness, and altered Wnt/beta-catenin signaling compared to untreated controls. Tumor growth was inhibited.

The Wnt finding matters for two reasons. First, it shows that PL's anti-angiogenic activity extends beyond the VEGF pathway and can operate through a distinct molecular mechanism. Second, it shows the effect across a second cancer type, raising the question of whether the three-mechanism pattern is general or specific to breast cancer.

A 2020 systematic review by Wong et al. placed Phellinus linteus among the most rigorously studied mushrooms for breast cancer suppression, contextualizing its anti-angiogenic evidence alongside other anti-proliferative and apoptotic effects in that specific cancer type.^[8]

The In Vivo Evidence: Beyond Cell Culture

Cell culture studies tell you what a compound can do to a cell under controlled conditions. Animal studies test whether those effects translate to a whole organism with a functional immune system, vascular network, and tumor microenvironment.

Tsuji et al. (2010) tested Phellinus linteus extract in athymic nude mice bearing human prostate cancer xenografts.^[5] Athymic nude mice lack a functional T-cell system, which allows human cancer cells to grow in them without being rejected. This is the standard preclinical model for testing anti-tumor compounds. Tumor growth was suppressed in the PL-treated group. The fact that this was prostate cancer, not breast cancer, again suggests PL's anti-tumor activity is not restricted to a single cancer type.

Zhu et al. (2007) studied prostate cancer in cell culture and found that Phellinus linteus activated multiple apoptotic pathways in LNCaP prostate cancer cells, including caspase 2, caspase 8, and endoplasmic reticulum stress signaling.^[6] This apoptosis data is distinct from the angiogenesis data: it shows PL affecting cancer cells directly, not just their blood supply. Anti-angiogenesis and apoptosis induction appear to be complementary mechanisms rather than alternatives. For the apoptosis data, see Meshima and Cancer Cell Apoptosis.

Wang et al. (2023) brought the most recent data, using a Sanghuangporus sanghuang extract, the modern taxonomic designation for the Phellinus linteus lineage after reclassification.^[7] Their extract inhibited A549 and H1650 lung cancer cell migration and invasion dose-dependently at 6 to 9 mg/mL, suppressed STAT3 (a transcription factor that promotes angiogenesis and tumor survival), Bcl-2, CDK4, and Cyclin D1. Tumor growth inhibition was confirmed in vivo. The use of the new taxonomic name is worth noting for literature searches: studies published after the reclassification appear under Sanghuangporus sanghuang rather than Phellinus linteus.

What the Evidence Doesn't Yet Show

The preclinical picture from the studies above is coherent and mechanistically specific. But there are three important gaps between what the laboratory shows and what can be claimed about clinical application.

No human angiogenesis data exists. Every study measuring VEGF suppression, VEGFR-2 inhibition, or microvessel density reduction was conducted in cell culture or animal models. The mechanism for how Phellinus linteus reaches the tumor microenvironment in a human patient, at what concentrations, and whether it suppresses VEGF at a clinically meaningful level has not been studied. Animal models are a necessary step toward human trials; they are not a substitute for them.

The preclinical models don't share a standard extract. Sliva 2008 used an aqueous extract, Lee 2010 used a methanol extract, Song 2011 used a protein-bound polysaccharide fraction. These are not the same product. Whether any commercial Phellinus linteus preparation delivers the same active fractions at the same concentrations used in these studies is not established.

The dose-response in humans is unknown. Wang 2023 found effects at 6 to 9 mg/mL in cell culture, but cell culture concentrations do not translate directly to oral doses in humans. Pharmacokinetics (absorption, distribution, metabolism, and excretion) determine how much of any compound reaches a tumor from an oral dose. None of these parameters have been measured for Phellinus linteus anti-angiogenic fractions in humans.

For how Phellinus linteus anti-angiogenic mechanisms compare to pharmaceutical drugs designed for the same purpose, see Meshima vs. Pharmaceutical Angiogenesis Inhibitors. For the most VEGF-specific analysis in this cluster, see Phellinus linteus and VEGF Inhibition. For clinical context from a more widely studied mushroom, see Ganoderma lucidum as a Cancer Adjunct.

The Bottom Line

Phellinus linteus (meshima) disrupts tumor angiogenesis through three documented preclinical mechanisms: suppressing VEGF production via AKT inhibition in cancer cells (Sliva 2008), blocking VEGFR-2 activation in endothelial cells (Lee 2010), and disrupting Wnt/beta-catenin signaling in colon cancer xenografts (Song 2011). In vivo tumor growth suppression has been confirmed in both prostate and colon cancer mouse models. No human trial has tested these mechanisms in cancer patients, and the preclinical evidence is based on heterogeneous extract types across studies.

Frequently Asked Questions

Does Phellinus linteus have anti-angiogenic properties?

Yes, in laboratory and animal models. Multiple studies have found Phellinus linteus inhibits the formation of new blood vessels toward tumors through at least three mechanisms: suppressing VEGF secretion from cancer cells via AKT inhibition, blocking VEGFR-2 phosphorylation in endothelial cells, and disrupting Wnt/beta-catenin signaling in colon cancer models. Anti-angiogenic effects have been confirmed in cell culture (Sliva 2008, Lee 2010), mouse xenograft models (Song 2011), and in the chick chorioallantoic membrane assay (Lee 2010). No human trial has specifically measured Phellinus linteus's effect on tumor angiogenesis.

How does meshima cut off tumor blood supply?

Meshima appears to cut off tumor blood supply at three points in the angiogenesis process. First, it reduces VEGF secretion from cancer cells by blocking AKT kinase, the signaling protein that drives VEGF production. Second, it directly inhibits VEGFR-2, the receptor on blood vessel cells that VEGF activates to trigger capillary growth, preventing the VEGF signal from being received even when VEGF is present. Third, in colon cancer models, it disrupts Wnt/beta-catenin signaling, a pathway that governs vascular formation independently of VEGF. All three mechanisms come from preclinical studies.

What compounds in meshima inhibit angiogenesis?

Studies have identified beta-(1,3)-linked glucans and protein-bound polysaccharides as the primary anti-angiogenic compounds in Phellinus linteus. The Sliva 2008 and Lee 2010 studies used aqueous and methanol extracts respectively; Song 2011 used a protein-bound polysaccharide fraction. A 2023 systematic review by Qin et al. of Phellinus linteus polysaccharides identified structural features of the beta-glucan fractions responsible for anti-tumor and anti-angiogenic activity. The activity appears distributed across multiple compound classes rather than concentrated in a single molecule.

Can mushrooms stop tumors from growing blood vessels?

Several medicinal mushrooms, including Phellinus linteus (meshima), Ganoderma lucidum (reishi), and others, have shown anti-angiogenic activity in preclinical studies. Phellinus linteus has the most mechanistically specific anti-angiogenesis data in the published literature, with VEGF suppression, VEGFR-2 inhibition, and Wnt/beta-catenin disruption all documented. The evidence base is entirely preclinical: in vitro cell culture and animal models. No mushroom has been shown to inhibit tumor angiogenesis in a human clinical trial.

Is Phellinus linteus used in cancer treatment?

Phellinus linteus is not an approved cancer treatment in any country. The preclinical anti-angiogenic and anti-tumor data is extensive (multiple studies in breast, prostate, colon, and lung cancer models), but no randomized controlled trial has tested PL for cancer outcomes in humans. The only published human RCT of Phellinus linteus (Ku et al., 2022) studied immune effects in healthy or non-cancer populations, not tumor angiogenesis or cancer outcomes. In South Korea and parts of East Asia, Phellinus linteus is used as a traditional medicine and sold as a dietary supplement, but this use is not supported by clinical trial evidence.

Sources & References

1. 1RTHM-00349·Lee, Yeon Sil et al. (2010). “Anti-angiogenic activity of methanol extract of Phellinus linteus and its fractions..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
2. 2RTHM-00271·Sliva, D et al. (2008). “Phellinus linteus Extract in Breast-Cancer Cell Models: What This 2008 Study Actually Found.” British journal of cancer.Study breakdown →PubMed →↩
3. 3RTHM-00364·Sliva, Daniel (2010). “Medicinal mushroom Phellinus linteus as an alternative cancer therapy..” Experimental and therapeutic medicine.Study breakdown →PubMed →↩
4. 4RTHM-00437·Song, Kyoung-Sub et al. (2011). “Protein-bound polysaccharide from Phellinus linteus inhibits tumor growth, invasion, and angiogenesis and alters Wnt/β-catenin in SW480 human colon cancer cells..” BMC cancer.Study breakdown →PubMed →↩
5. 5RTHM-00367·Tsuji, Takanori et al. (2010). “Phellinus linteus extract sensitizes advanced prostate cancer cells to apoptosis in athymic nude mice..” PloS one.Study breakdown →PubMed →↩
6. 6RTHM-00240·Zhu, T et al. (2007). “Phellinus linteus activates different pathways to induce apoptosis in prostate cancer cells..” British journal of cancer.Study breakdown →PubMed →↩
7. 7RTHM-01817·Wang, Weike et al. (2023). “Sanghuangporus sanghuang extract inhibits the proliferation and invasion of lung cancer cells in vitro and in vivo..” Nutrition research and practice.Study breakdown →PubMed →↩
8. 8RTHM-00664·Wong, Jack Ho et al. (2020). “Mushroom extracts and compounds with suppressive action on breast cancer: evidence from studies using cultured cancer cells, tumor-bearing animals, and clinical trials..” Applied microbiology and biotechnology.Study breakdown →PubMed →↩